Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04025346
Other study ID # OM/190402/CAPSIMAX
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 17, 2019
Est. completion date March 30, 2020

Study information

Verified date December 2019
Source Vedic Lifesciences Pvt. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Capsimax™ is a proprietary Capsicum Extract that employs Beadlet Technology. In the previous study it has been used to investigate its effect in reducing body fat/weight and increase metabolic rate. In this study, Capsimax™ will be used to assess effect on Resting Energy Expenditure (REE) using Indirect Calorimetry.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date March 30, 2020
Est. primary completion date March 23, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Healthy, adult, male/female participants with age = 18 = 55 years.

- A Body Mass Index (BMI) between 18.5 to 29.9 kg/m2.

- Fasting blood sugar = 100 mg/dl

- Hemoglobin: Males = 11 g/dl and Females = 10 g/dl

- BP < 140/90 mmHg

Exclusion Criteria:

- Post-menopausal females

- History of hypo/ hyperthyroidism.

- History of significant neurological or psychiatric condition such as seizures, depression, or insomnia.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Capsimax
1 capsule to be taken before breakfast.
Micro Crystalline Cellulose
1 capsule to be taken before breakfast.

Locations

Country Name City State
India Vedic Lifesciences Pvt. Ltd. Thane Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Vedic Lifesciences Pvt. Ltd.

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of Investigational Product on Resting Energy Expenditure Assessed by Indirect Calorimetry From baseline to 4 hours.
See also
  Status Clinical Trial Phase
Completed NCT00070577 - Influence of Age and Sex on Alcohol Metabolism and Acute Responses N/A
Active, not recruiting NCT05488574 - Effects of Novel Breathing Behavior Modification Yoga Positioning Integrated Program on Weight Loss N/A
Recruiting NCT05582824 - Lactate Metabolism in the Hypoperfused Critically Ill
Recruiting NCT05443347 - Activity, Adiposity, and Appetite in Adolescents 2 Intervention N/A
Completed NCT05020808 - The Effect of a Plant Protein Isolate on Muscle Protein Synthesis in Humans at Rest and After Resistance Exercise N/A
Recruiting NCT06082726 - The Systemic Concentration of Short-Chain Fatty Acids After Delivery in the Small and Large Intestine of Healthy Volunteers N/A
Completed NCT04144426 - Meal Schedule Effects on Circadian Energy Balance in Adults N/A
Completed NCT03424395 - Personalized Dietary Program and Markers of Wellness N/A
Completed NCT02441296 - Carbohydrate and Metabolism: a Pilot Study N/A
Completed NCT00176085 - Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH Phase 1
Completed NCT00245986 - Effect of Genetics on Metabolism of Efavirenz Phase 4
Completed NCT04078646 - Influence of Proteins on the Bioavailability of Carotenoids N/A
Active, not recruiting NCT06033898 - Inactivity Duration on Lipid Metabolism N/A
Active, not recruiting NCT06250270 - Effects of Casein Protein on Metabolism When Taken Prior to Sleep and in the Morning Early Phase 1
Completed NCT06285578 - Effects of Probiotic and HIIT in Obese Women N/A
Completed NCT04255368 - Choline Source, Gut Microbiota and Trimethylamine-N-oxide Response N/A
Recruiting NCT06360796 - Study of Pharmacokinetics and Metabolism on [(14)C]ADC189 Phase 1
Recruiting NCT02005003 - Cognitive and Metabolic Effects of a Probiotic Supplement N/A
Completed NCT03146728 - Finding the Optimal Voluntary Exercise Parameters for Those Living With Quadriplegia N/A
Completed NCT00692510 - Drug Interaction Study Between AZD3480 and Cytochrome P450 Phase 1